European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching

Bone Marrow Transplantation

Volumn 20, Issue 1, 1997, Pages 11-19

  Devergie, A ^a   Apperley, J F ^b   Labopin, M ^c   Madrigal, A ^d   Jacobsen, N ^e   Carreras, E ^f   Prentice, H G ^g   Jouet, J P ^h   Kolb, H J ⁱ   Herstenstein, B ^j   Bacigalupo, A ^k   Evensen, S A ^l   Ljungman, P ^m   De Witte, T ⁿ   Reiffers, J ^o   Nagler, A ^p   Clark, R E ^q   Goldman, J M ^b   Gratwohl, A ^r  

^a SAINT LOUIS HOSPITAL   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d Anthony Nolan Bone Marrow Research Institute   (United Kingdom)

^e University of Copenhagen   (Denmark)

^f HOSPITAL CLÍNIC   (Spain)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j Abteilung Innere Medizin   (Germany)

^k UNIVERSITY OF GENOA   (Italy)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o HAUT LÉVÊQUE HOSPITAL   (France)

^p HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^q ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^r UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Chronic myeloid leukemia; Unrelated donor bone marrow transplant

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SIBLING; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0030857652     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700844     Document Type: Article

References (44)

1. Gift RA, Buckner CD, Thomas ED et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; 2: 621-623.
2. Goldman JM, Baughan ASJ, McCarthy DM et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 1982; 2: 623-625.
3. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
4. Gratwohl A, Hermans J, Niederwieser D et al for the Chronic Leukemia Working party of the European Group for Bone Marrow Transplantation. Bone marrow transplantation for chronic myeloid leukemia: long term results. Bone Marrow Transplant 1993; 12: 509-516.
5. Talpaz M, Kantarjian HM, McCredie KB et al. Hematologic remission and cytogenetic improvement induced by recombinant human interteron alpha A in chronic myelogenous leukemia. New Engl J Med 1986; 314: 1065-1069.
6. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engi J Med 1994; 330: 820-825.
7. Allan NC, Richards SM, Sheperd PC. UK Medical Research Council: randomized multicentre trial of interteron alfa for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. The UK medical Research Council's working parties for therapeutic trials in adult leukaemias. Lancet 1995; 345: 1392-1397.
8. McGlave PB, De Fabritis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
9. McGlave D, Scott E, Ramsay N et al. Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia. Blood 1987; 70: 877-881.
10. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728-1732.
11. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993; 119: 207-214.
12. Bearman SI, Mori M, Beatty PG et al. Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. Bone Marrow Transplant 1994; 13: 31-35.
13. Davies SM, Ramsay NKC, Haake RJ et al. Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 1994; 13: 51-57.
14. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA system, 1994. Tissue Antigens 1994; 44: 1-18.
15. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
16. Jordan F, McWhinnie AJ, Turner S et al. Comparison of HLA-DRB1 typing by DNA-RFLP, PCR-SSO and PCR-SSP methods and their application in providing matched unrelated donors for bone marrow transplantation. Tissue Antigens 1995; 45: 103-110.
17. Kaplan EL, Meier P. Non parametric estimation from incomplete information. J Am Star Assoc 1958; 53: 457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
20. Beatty PG, Dahlberg S, Mickelson EM et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988; 45: 714-718.
21. Bradley BA, Giljs WR, Gore SM, Klouda PT. How many HLA typed volunteer donors for bone marrow transplantation (BMT) are needed to provide an effective service? Bone Marrow Transplant 1987; 2 (Suppl. 1): 79 (Abstr.).
22. Beatty PG, Ash R, Hows JM, McGlave PB. The use of unrelated bone marrow donors in the treatment of chronic myelogenous leukemia: experience of four centers. Bone Marrow Transplant 1989; 4: 287-290.
23. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
24. McGlave P, Barsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program: Blood 1993; 81: 543-550.
25. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14: 349-352.
26. Cullen M, Erlich H, Klitz W, Carrington M. Molecular mapping of a recombination hotspot located in the second intron of the human TAP2 locus. Am J Hum Genet 1995; 56: 1350-1358.
27. Santamaria P, Reinsmoen NL, Linstrom AL et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1 and HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 1994; 83: 280-287.
28. Al-Daccak R, Loiseau P, Rabian C et al. HLA-DR, DQ and/or DP genotypic mismatches between recipient-donor pairs in unrelated bone marrow transplantation and transplant clinical outcome. Transplantation 1990; 50: 960-964.
29. Petersdorf EW, Smith AG, Mickelson EM et al. The role of HLA-DPB1 disparity in the development of acute graft versus host disease following unrelated donor bone marrow transplantation. Blood 1993; 81: 1923-1932.
30. Spencer A, Brookes PA, Kaminski E et al. Cytotoxic T-lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Transplantation 1995; 59: 1302-1308.
31. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 1988; 108: 806-814.
32. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
33. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2354-2363.
34. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
35. Beelen DW, Graeven U, Elmaagacli AH et al. Prolonged administration of interferon α in patients with chrome-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-2990.
36. Devergie A, Reiffers J, Vernant JP et al. Long-term follow up after bone marrow transplantation for chrome myeloid leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379-386.
37. Cosset JM, Girinski T, Malaise E et al. Clinical basis for TBI fractionation. Radiother Oncol 1990; 18 (Suppl. 1): 60-67.
38. Apperley JF, Mauro Fr, Goldman JM et al. Bone marrow transplantation of chronic myeloid leukaemia in first chronic phase: importance of a graft versus leukaemia effect. Br J Haematol 1988; 69: 239-245.
39. Drobyski Wr, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft versus host disease prophylaxis on engraftment, relapse and disease free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-1987.
40. Kolb HJ, Schattenberg A, Goldman JM et al for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86: 2041-2050.
41. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
42. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes fo relapse of chronic myeloid leukemia after bone marrow transplantation: separatton of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
43. Petersdorf EW, Stanley JF, Martin PJ, Hansen JA. Molecular diversity of the HLA-C locus in unrelated marrow transplantation. Tissue Antigens 1994; 44: 93-99.
44. Espérou H, Tatari Z, Fortier C et al. Influence of donor/recipient HLA-C disparity in 70 unrelated bone marrow transplantation. Blood 1995; 86 (Suppl. 1): 291a (Abstr.).